Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'

Pompe, R S; Von Bueren, André; Mynarek, M; von Hoff, K; Rutkowski, S

doi:10.1016/j.ejca.2015.11.011

Scientific article

Comment

English

Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'

ContributorsPompe, R S; Von Bueren, André

; Mynarek, M; von Hoff, K; Rutkowski, S

Published inEuropean journal of cancer, vol. 56, p. 181-182

Publication date2016-03

First online date2016-01-13

Keywords

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cerebellar Neoplasms / therapy
Female
Humans
Male
Medulloblastoma / therapy

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

POMPE, R S et al. Reply to letter that comments on “Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy”. In: European journal of cancer, 2016, vol. 56, p. 181–182. doi: 10.1016/j.ejca.2015.11.011